Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dengue vaccine in HIV-positive adults
NCT02741128Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2019
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dengue fever and dengue hemorrhagic fever (DHF) comparing CYD Dengue vaccine group with Placebo vaccine group (2 arms). Primary endpoints: Percentage of Participants With Unsolicited Systemic Adverse Event (AE), Percentage of Participants With Solicited Injection-Site Reactions and 3 more. Started Nov 2019; status: completed.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue feverdengue hemorrhagic fever (DHF)
Beyond the preview
Go deeper on NCT02741128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741128.